Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) EPS (Weighted Average and Diluted) (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed EPS (Weighted Average and Diluted) for 16 consecutive years, with -$0.02 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 37.04% year-over-year to -$0.02, compared with a TTM value of -$0.0 through Oct 2025, up 88.24%, and an annual FY2025 reading of -$0.0, up 88.24% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.02 for Q4 2025 at Pharma-Bio Serv, down from $0.01 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.02 in Q3 2023 and bottomed at -$0.21 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.01, with a median of $0.01 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 3457.93% in 2021, then skyrocketed 144.44% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.21 in 2021, then skyrocketed by 104.77% to $0.01 in 2022, then tumbled by 120.44% to -$0.0 in 2023, then tumbled by 1217.01% to -$0.03 in 2024, then surged by 37.04% to -$0.02 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for PBSV at -$0.02 in Q4 2025, $0.01 in Q3 2025, and $0.0 in Q2 2025.